先天性心脏病患者手术时的输血管理 关键信息 我们找到19项研究，比较先天性心脏病儿童心脏手术中不同红细胞输注策略。但证据质量不足以得出可靠结论。需更多研究。 先天性心脏病是什么？ 先天性心脏病是指人天生就有的心脏发育问题。这意味着心脏发育不完全或不正常。每1,000名活产婴儿中，就有4至9名患有此病。在大多数情况下，孩子需要手术才能够健康的生活和成长。成人也常常需要进行手术来处理先天性心脏病。 为什么在心脏手术中管理输血很重要？ 病患通常需要在心脏手术前、手术中或手术后进行红细胞输注。大多数病患会在使用体外循环（cardiopulmonary bypass, CPB）机器的情况下进行手术，这台机器在手术过程中充当他们的心脏和肺部功能。现在，接受心脏手术的病患存活率比过去高，我们的目标是使手术更加安全。有一些研究表示，红细胞输注可能会使病人变得更虚弱。如果是这样，避免不必要的输血会是更好的选择。 我们想了解什么？ 我们希望了解红细胞输注的管理如何影响心脏手术后病人的治疗结局。红细胞输注是否会影响病人的短期和长期存活率、严重副作用（例如中风、肾衰竭、感染、血栓、出血），以及病人在加护病房和医院住院的时间？ 我们做了什么？ 我们检索了医学资料库找寻相关的研究。我们找寻最可靠的研究类型，即随机对照试验（“随机试验”）。我们比较并总结了各项试验的结果，并根据其研究方法、参与人数等因素，评估...

不同的营养支持是否影响成人胰十二指肠切除术后的恢复与并发症？ 关键信息 - 肠道营养可能不会增加并发症风险，但与肠外营养相比，可能减少住院天数。 - 与空肠造口灌食相比，经口营养的并发症或住院天数可能没有明显差异，但证据不确定。 - 这些不同类型的营养方式如何影响胰十二指肠切除术后的患者，需要更多证据来增加可信度。 什么是胰十二指肠切除术？ 胰十二指肠切除术，也称为 Whipple 手术，是一种切除胰腺头的手术。通常用于癌症治疗，也可以用于良性肿瘤和慢性胰腺炎，目的是移除所有癌组织以帮助患者延长生命。 胰十二指肠切除术后营养支持有哪些？ 手术后，患者需要营养支持来帮助他们恢复，可以利用三种方式进行： - 经口进食：通常从液体开始，逐渐添加固体食物。 - 肠道灌食 (胃灌食或空肠灌食)：利用导管将营养直接输送到胃或小肠。 - 静脉营养：经由中心或周边静脉输送营养成份，可采取全静脉营养 (完全非肠道营养) 或部分静脉营养。 我们想了解什么？ 我们想知道不同的营养支持方式是否影响成人胰十二指肠切除术后的恢复与并发症。 我们做了什么？ 我们评价多个医学资料库中的研究，时间截至 2022 年 10 月止，纳入了比较不同营养支持方式和不同提供时间，并将重点放在医院进行的研究。我们分析了 17 项研究共包含 1897 名患者 ，其中 8 项研究适合进行详细的统计分析 (meta分析)。 我们发...

Catherine Spencer OBE, who served as the Cochrane Collaboration’s Chief Executive Officer since 2022, has decided to step down from the role.

Catherine has led Cochrane through transformational change, developing a new strategy for a more evidence-informed world and ensuring the organization is well-placed to deliver it. She has helped to cement Cochrane’s reputation as a world-leading source of trustworthy evidence and expand the charity’s reach and impact around the world.

“I have been so fortunate to work with incredibly talented and loyal colleagues, Board Members and community members,” said Catherine. “All have worked hard to ensure that Cochrane has a great future and is a wonderful environment in which to work and grow. I wish all the team well as they focus on the continued success of Cochrane.”

The Governing Board has appointed Dr Karla Soares-Weiser as Acting CEO while they prepare to recruit the next CEO. Cochrane’s Deputy Editor-in-Chief, Toby Lasserson, will serve as Acting Editor-in-Chief.

Dr Susan Phillips, Chair of Cochrane’s Governing Board, said:

“The Governing Board would like to thank Catherine for her valued contribution to Cochrane and Cochrane community. In her time as CEO, she has ensured that the organization has a warm and collaborative culture that fosters innovation and trust.

“We wish to acknowledge the important contribution Catherine has made towards stabilizing Cochrane’s operations, developing the 2024-2027 Organizational Strategy, supporting Cochrane’s transition to a centralized editorial service and implementing the Roadmap to Open Access.

“Consequently, Cochrane is in a strong position, and we anticipate building on these achievements. Our priorities will be to strengthen Cochrane’s evidence synthesis model, including our use of AI tools, and to develop business models and methods which make us more responsive to funders’ needs.”

Preparations to recruit the next CEO will be led by Cochrane’s Governing Board.

Wednesday, March 12, 2025

March 2025 marks the third anniversary of Cochrane’s commitment to Public Involvement in Health and Social Care Research, a pledge launched in 2022. This commitment underscores Cochrane's ongoing efforts  to enhance its practice of public involvement, ensuring that the voices of the users of our evidence are at the heart of health and social care evidence.

Excellent public involvement is an essential part of health and social care research and improves the quality and impact of research. Excellent public involvement is inclusive, values all contributions, ensures people have a meaningful say in what happens, and influences outcomes, as set out in the UK Standards for Public Involvement.

Cochrane is proud to be one of the thirty two organizations in partnership on this important initiative. Together, partners connect during quarterly Learning and Sharing meetings to share best practices and new developments, amplifying excellent public involvement and maximising resources for optimised efforts and impact.

Reflecting on this milestone, April English, Cochrane’s Consumer Engagement Manager, states: “Our commitment to public involvement is key to advancing health and social care research and demonstrating our value for the invaluable contributions of patients and the public, ultimately improving the quality and impact of research.”

“People have the right to be involved in all health and social care research,” Ana Beatriz Pizarro, member of the Consumer Network Executive, reflects. “People’s lived experiences should be a key driver for health and social care research.”

Key Achievements and Initiatives

Over the past three years, Cochrane has taken significant steps to strengthen public involvement, including:

• Cochrane’s Consumer Network: In 2025, three new members joined the Consumer Network Executive, and as of January 2025, over 2,500 members have joined the Consumer Network. Both, strengthening the community of people interested in high-quality health evidence, and in helping to be a part of producing and sharing evidence.
• Reporting Consumer Involvement: Since 2024, all new Cochrane reviews must report on consumer involvement.
• Consumer Representation on Editorial Board: The Editorial Board is responsible for supporting Cochrane’s Editor in Chief and overseeing the production of Cochrane Reviews and other Cochrane Library content. The Editorial Board includes representation from the Consumer Network.
• Consumer Peer Review of Submitted Cochrane Reviews and Protocols: Recent consumer peer reviews include Electronic cigarettes for smoking cessation, Interventions implemented through sporting organisations for promoting healthy behaviour or improving health outcomes, Prevention of self‐harm and suicide in young people up to the age of 25 in education settings, and Water fluoridation for the prevention of dental caries. 
• The Co-Production Methods Group: Launched in October 2023, this group advances research on co-production methods, shares best practices, and supports learning to help systematic review authors engage meaningfully with healthcare consumers.
• Evidence Essentials:  A free, online learning module co-produced by healthcare consumers, researchers, and Cochrane specialists, helping people understand health evidence and make informed health choices. In 2024, module six was launched on critical appraisal of rapid reviews.
• Learning Live Webinars:  A series of free webinars tailored for different audiences, including review authors and the public, providing guidance on engaging with Cochrane evidence and making research more accessible.

Cochrane’s Framework for Public Involvement

Cochrane’s framework for consumer engagement and involvement focuses on five key elements:

1. Engagement: Strengthening communication, evidence dissemination, recruitment, and learning opportunities for consumers.
2. Co-Production: Increasing consumer involvement in evidence production and governance to align research with user needs.
3. Accessibility: Enhancing health literacy and making Cochrane evidence easier to access and understand.
4. Strategic Partnerships: Collaborating with patient groups and other stakeholders to advance engagement, co-production, and advocacy efforts.
5. Evaluation and Reporting: Establishing key engagement and involvement metrics for evaluating and reporting the impact of Cochrane’s engagement and involvement activity. 
   
   
   

How to Get Involved?

There are many ways to play a part in health and social care research  at Cochrane.

Join Cochrane's Consumer Network, a large and growing community of people across the world. We welcome patients, carers and the public who are interested in getting involved in and sharing high-quality health evidence.

Cochrane Engage and Cochrane Crowd are always looking for volunteers to get involved with research.

• Learn more about Cochrane’s commitment to healthcare consumers
• Contact the Cochrane’s Consumer Engagement Manager or Cochrane’s Consumers Network Executive at consumers@cochrane.org 
  

 

Tuesday, March 11, 2025

质子泵抑制剂对患有反流病的早产儿的安全性和有效性 关键信息 -- 胃食管反流在早产儿中很常见 -- 目前的证据尚无法确定质子泵抑制剂 （Proton pump inhibitors, PPIs） 治疗早产儿反流是否安全且有效。 什么是胃食管反流，它与胃食管反流病有何不同？ 胃食管反流是指胃内容物回流至食管（连接咽喉和胃的管道）。这种情况在新生儿中很常见。早产儿更容易出现反流，因为他们的胃与食管连接处的连接较为松弛。他们常使用从嘴巴或鼻子通到胃里的饲管，这可能会进一步使胃与食管的接合处打开，增加胃食管反流的风险。 当反流导致体重增加缓慢、喂养不耐受和疼痛等症状时，应考虑胃食管反流病 （Gastroesophageal reflux disease, GERD）。 在早产儿中，GERD 可能会导致其他症状，如呼吸暂停、心动过缓（心率减慢）或低氧血症（血液中氧含量下降）。上消化道内含有感应器，一旦被刺激，可能会引发心率减慢或血氧下降的反应。这些在早产儿中更敏感，反流可能会触发它们。 如何治疗胃食管反流病? GERD最常见的治疗方法是：在喂食期间或喂食后改变婴儿的姿势，改变配方奶的种类或稠度，或使用减少胃酸的药物。PPIs是针对该人群所广泛使用的药物，但它们具有副作用，例如增加感染风险、肠道发炎、骨密度变化和导致儿童肥胖。目前评估PPIs对治疗早产儿GERD的有效性和安全性的研究并不多。...

Title:  Digital Marketing Manager
Specifications: Permanent – Full Time
Salary: £52,000 per annum
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 19 March, 2025

The Digital Marketing Manager is an exciting new role that reflects the strategic importance of digital marketing to Cochrane, an internationally renowned charity providing high-quality health evidence.

You will establish and oversee the organization’s digital marketing function, recruiting and managing a part-time (0.6 FTE) Digital Marketing Officer. Together you will deliver high-quality, targeted digital marketing campaigns that inspire engagement and support from a range of audiences.

This role will oversee both brand marketing for diverse audiences and B2B/B2C marketing aimed primarily at universities and academics. Brand marketing will involve ownership of Cochrane’s social media accounts and oversight of email marketing, working closely with colleagues who manage the CRM (SugarCRM). Commercial marketing will include promoting academic conferences, on-demand training courses, and specialist software (SaaS).

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 19 March, 2025. We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24 March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits

 

Friday, March 7, 2025 Category: Jobs

A new Cochrane review has found evidence that music-based therapy may benefit people living with dementia, particularly by improving symptoms of depression. 

Dementia is a collective term for progressive degenerative brain syndromes that affect memory, thinking, behaviour and emotion. Alzheimer’s Disease International reported that there were 55 million people with dementia worldwide in 2019, a figure predicted to increase to 139 million by 2050. While some medicines are available, the therapeutic use of music is considered a relatively simple and inexpensive approach that remains accessible even in the later stages of dementia.  

The research team from several institutions in the Netherlands examined evidence from 30 studies involving 1,720 people. The studies investigated the effects of music-based therapeutic interventions on emotional well-being including quality of life, mood disturbance, behavioural problems, social behaviour, and cognition. Most participants were in care homes, with interventions delivered either individually or in group settings. 

The trials were primarily conducted in high-income countries, including Australia, Taiwan, the US, and various European countries.  Almost all the therapies included active elements (such as playing instruments), often combined with receptive elements (such as listening to live music provided by a therapist).

"This review increases our understanding of the effects of music therapy and strengthens the case for incorporating music in dementia care, particularly in care home settings.

“Music therapy offers benefits beyond those of other group activities, helping to support mood and behaviour in a way that is engaging and accessible, even in later stages of dementia. Care home managers should consider integrating structured musical sessions as part of a person-centred approach to dementia care.”

- Jenny van der Steen, lead author from Leiden University Medical Center and Radboudumc Alzheimer Center.

The findings suggest that music-based therapy probably improves depressive symptoms and may improve overall behavioural problems by the end of treatment. Music therapy is unlikely to significantly impact agitation, aggression, emotional well-being, or cognition but, when compared to other interventions, there is some evidence that it may improve social behaviour and could decrease anxiety. 

Long-term effects, beyond four weeks after treatment, may be smaller but remain uncertain due to the limited number of trials monitoring effects after treatment ends.

The review also highlights the growing recognition of non-pharmacological interventions in dementia care. 

“Music therapy is a drug-free way of helping people feel less sad and less anxious. We hope that the higher quality of recent studies and increasing evidence-base will result in more attention being given to music therapy and other non-pharmacological approaches.

"Looking at the effect sizes, music therapy is a reasonable alternative to pharmacological approaches and is much more person-centred.”

- Annemieke Vink, co-author from ArtEZ University of the Arts who has first-hand experience delivering music therapy to people with dementia.

The review underscores the need for further research into the long-term effects of music-based therapy particularly in community settings. Much of the existing evidence comes from care homes, so expanding studies to community-based environments could provide valuable insights into how music therapy can be integrated into everyday life for people living with dementia.

• Read the Cochrane review and the plain language summary
• Read the press release in Spanish

 

Wednesday, March 5, 2025

Title:  Systematic Reviewer
Specifications: Permanent – Part time (0.6 FTE)
Salary: £45,000 per annum (£27,000 per annum at 0.6 FTE)
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 17 March, 2025

As a Systematic Reviewer you will assist with the provision and delivery of commissioned systematic reviews and review tasks for Cochrane Response, Cochrane’s evidence consultancy unit.

Cochrane Response provides a broad range of literature review and evidence synthesis services to international policy makers and guideline developers to support evidence informed healthcare decision making. We work closely with Cochrane networks to increase Cochrane’s capacity to respond to requests for commissioned evidence reviews and tailored evidence services.

This position is aligned with Cochrane’s strategy to secure the long-term sustainability of the organisation by ensuring the success of Cochrane Response as a business unit that produces relevant information to guide healthcare decisions and responds to the needs of our stakeholders.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 17th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24th March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits.

 

Tuesday, March 4, 2025 Category: Jobs

We are delighted to announce a new, joint Methods Group between the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE) focusing on artificial intelligence (AI) and automation in evidence synthesis. 

The rapidly growing evidence base and the increasing complexity of methods makes completing timely, high-quality, and comprehensive evidence synthesis, more and more challenging. Artificial intelligence (AI) and automation promises to help address this, and make it possible to keep up with the demand and expectations of users of evidence synthesis. But to realize this potential, we - as a collective across the whole evidence synthesis ecosystem - need to ensure AI doesn’t compromise on the principles of research integrity in which evidence synthesis was built. Therefore, this Methods Group will help define and support responsible AI use across four of the leading evidence synthesis organizations, including the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE).   

As a Methods Group, we aim to: 

• Spearhead methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 
• Define best practice and ensure guidance for accepted methods is up to date. 
• Support the implementation of new or amended methods by acting as an advisor or through involvement in methods implementation in our respective evidence synthesis organizations.  

Spearheading methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 

We are part of the International Collaboration for Automation in Systematic Reviews (ICASR) and recommend those who want to share and discuss AI methods research, developments and opportunities, do so via the ICASR LinkedIn group, as we will as a Methods Group. 

Across our Methods Group, we are also involved in other key developments in the evidence synthesis ecosystem, including the Evidence Synthesis Infrastructure Collaborative safe and responsible use of AI working group. 

Our aim is for the Methods Group to work across these organizations and developments in the field and facilitate discussion and critical thinking, particularly around standards for accuracy, evaluations and validation, with events, webinars and other activities.  

Defining best practice and ensuring guidance for accepted methods is up to date. 

We are involved the responsible AI use in evidence synthesis recommendations and guidance (RAISE), which offers tailored advice for a diverse range of roles in the evidence synthesis ecosystem. Whether you're an evidence synthesist, methodologist, AI developer, or an organization or publisher involved in evidence synthesis, this guidance is a first step to help clarify your responsibilities and alleviate some of the concerns around AI use. For more information see the RAISE Open Science Framework project page. 

One of our first actions as a Methods Group will be to  provisionally endorse the next version of the RAISE recommendations and guidance for use in Cochrane, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE), which  is due to be released soon. 

Supporting the implementation of new or amended methods by acting as an advisor or through involvement in the methods implementation projects.  

The Methods Group has individuals from across four of the major evidence synthesis organizations, and even though implementation of AI and automation is the responsibility of each organization individually, by coming together we can aim to align best practice and share lessons learned on effective approaches. Our implementation will be based on the RAISE recommendations, with more details being shared in the coming months.  

As a first step, we are in the process of defining our position on AI and automation for researchers and authors within our organizations, to ensure they have clarity and are empowered to use them in their evidence synthesis. 

Our implementation will also consider how we can we improve AI literacy across our organizations, including how we can work with methodologists and trainers, so researchers and editors have the skills they need to ensure AI is used responsibly and reported transparently.  

 

Methods Group Convenors: 

• Ella Flemyng (Cochrane, UK)
• Gerald Gartlehner (University for Continuing Education Krems and Cochrane Austria, Austria)
• Zoe Jordan (JBI, Australia)
• Biljana Macura (Stockholm Environmental Institute and the Collaboration for Environmental Evidence, Sweden)
• Joerg Meerpohl (University of Freiburg and Cochrane Germany, Germany)
• Will Moy (Campbell, UK)
• Anna Noel Storr (Cochrane, UK)
• James Thomas (UCL, UK) 

Want to find out more? 

Register for the webinar on ‘Recommendations and guidance on responsible AI in evidence synthesis’ on 3 June 2025, part of the Artificial Intelligence (AI) methods in evidence synthesis series, to find out about why we all need to embrace responsible AI and how this Methods Group will support it. 

Also see our AI Methods Group website, which includes a news and events section. You can also follow each individual organization for more news and information as the Group develops. 

 

 

Friday, February 28, 2025

Title:  Head of Publishing Operations 
Specifications: Permanent – Full Time 
Salary: £63,000 per annum 
Location: (Remote) resident in the UK, Germany or Denmark.  
Directorate: Publishing and Technology Directorate 
Closing date: 14 March, 2025 

We are seeking an experienced and proactive Head of Publishing Operations to lead and manage Cochrane’s publishing systems and processes. In this key role, you will act as liaison between internal teams, external technology suppliers, and our publishing partner, ensuring smooth, efficient and innovative xml-first workflows from submission to publication. You will oversee the performance of our publishing technology, manage vendor relationships, and drive continuous improvements to our production processes. With a strong focus on operational excellence, stakeholder collaboration, and author experience, you will play a pivotal role in ensuring Cochrane’s publishing systems and processes are efficient, reliable, and aligned with our strategic goals. 

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally. 

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate. 

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. 

How to apply 

• For further information on the role and how to apply, please click here. 
• The deadline to receive your application is 14th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible. 
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Interviews will be held on w/c 24th March, 2025.
• Read our Recruitment Privacy Statement
• Read our Candidate pack for more information on the hiring process and staff benefits 

Friday, February 28, 2025 Category: Jobs

Title:  Head of Finance
Specifications: Permanent – Full Time
Salary: £63,000 per annum
Location: (Remote) based in the UK, Germany or Denmark.
Closing date: 7 March, 2025

As an experienced and qualified Accountant, you will lead and manage Cochrane’s finance functions; developing and implementing strategies, policies and systems to ensure that they are provided in an effective and efficient manner to support the strategic aims and operational activities of the organisation. You will also contribute to Cochrane’s financial sustainability through inputs to fundraising, product & business development and robust financial management.

Reporting to the Director of Finance & Corporate Services, you will lead our small, friendly and dedicated Finance Team, responsible for the effective management and control of the financial function of a medium sized dynamic Charity. This is a pivotal role leading the financial outcomes, which will directly support senior leadership and top-level decision making and closely partner an array of key non-finance colleagues across the Charity.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace.

So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 7 March 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on 20 and 21 March 2025.
• Read our Recruitment Privacy Statement
• Read our Candidate pack for more information on the hiring process and staff benefits

Monday, February 24, 2025 Category: Jobs

针刺治疗子宫内药物暴露后新生儿戒断综合征 关键信息 •由于缺乏证据，我们无法就针灸对子宫内接触药物引起的新生儿戒断综合征婴儿的益处和风险得出任何结论。 •需要精心设计和报告的大型研究来了解更多关于针灸的益处和风险，包括对针灸技术、部位、时间和应用进行比较的研究。 什么是新生儿戒断综合征？ 新生儿戒断综合征是一种药物戒断综合征，大多发生在胎儿在子宫内接触阿片类药物（如海洛因和美沙酮）后。新生儿可能出生时就对药物产生身体依赖，导致出生后出现戒断症状，​​例如尖叫、睡眠-觉醒周期紊乱和震颤。新生儿戒断综合征的诊断采用标准化戒断评估，例如芬尼根评分。 什么是新生儿戒断综合征？ 与未患 NAS 的新生儿相比，患有 NAS 的新生儿出生后需要接受治疗，并且住院时间更长。新生儿戒断综合征的治疗包括多种多模式治疗以缓解戒断症状，​​例如襁褓、同室喂养和母乳喂养。如果标准化评估超过某个阈值，则对新生儿进行口服阿片类药物治疗。然而，最佳的新生儿戒断综合征治疗仍存在争议。针灸已被提议作为一种潜在的干预。针灸涉及对身体特定穴位的刺激，可以通过插入细金属针（“侵入性”）或使用不穿透皮肤的技术（“非侵入性”），例如指压和激光。 我们想知道什么？ 我们的目标是确定针灸对患有新生儿戒断综合征的婴儿的益处和风险。主要结局是药物治疗持续时间（药物治疗）、不良事件（伤害）和住院时间。 我们做了什么？ 我们检索了比较针...

心血管训练是否可以缓解抗癌治疗之前、期间或之后的癌症相关疲劳？ 关键信息 抗癌治疗期间进行心血管训练可能会在长达12周的时间内略微减轻癌症相关的疲劳。 心血管训练对癌症相关疲劳和生活质量的长期影响尚不确定，并且没有关于抗癌治疗前心血管训练效果的证据。 我们发现正在进行的有关癌症治疗前、治疗期间和治疗后心血管训练的近50项研究，这些研究将在研究结局公布后补充证据。 什么是癌症相关性疲劳？ 癌症相关疲劳是一种长期极度疲劳的感觉。它可能是由癌症治疗或癌症本身引起的。这是癌症患者最常见的症状。它不能通过休息来缓解，而且会影响身心。 什么是心血管训练？ 心血管训练是任何使用臀部和大腿大肌肉群并增加心率和呼吸频率的活动。例如步行、跑步、骑自行车和游泳。 为什么心血管训练可能对癌症相关疲劳有效？ 癌症相关疲劳与身体对细胞因子的反应有关，细胞因子调节组织和器官如何增大（称为细胞生长）。癌症或癌症治疗可能会产生称为促炎细胞因子的蛋白质，这种蛋白质会导致或加重炎症（身体对损伤或疾病的反应，包括肿胀和疼痛等症状）。心血管训练有助于减少炎症。 我们想了解什么？ 我们想知道与不进行训练相比，心血管训练是否能减轻癌症相关的疲劳。我们探索了短期（最长12周）、中期（最长六个月）和长期（超过六个月）的影响。我们还研究了生活质量、不良影响、焦虑和抑郁。 我们做了什么？ 我们检索了关于抗癌治疗之前、期间或之后进行心...

二氧化碳检测在确定通过鼻子或嘴插入的导管是否意外放置在儿童的气道而不是胃中的准确性如何？ 关键信息 • 没有足够的证据表明二氧化碳（CO₂）测试应添加到当前的检查程序中。 • 需要更多的研究来确定CO₂测试是否对正在插入胃肠管的儿童有益。 为什么知道管子是否意外插入气道很重要？ 通过鼻子或嘴巴插入一根薄的柔性塑料管（肠胃管）是儿童的常见医疗程序，当儿童无法通过口腔服用时，可以提供营养和药物。许多儿童需要这种手术，无论是短期还是长期。需要喂食管的原因有几个，包括无法吞咽或影响耐受足够营养摄入水平的能力的医疗条件。 大多数管子插入和使用时都没有发生事故。然而，如果一根管子被错误地放入肺部并用于提供营养或药物，这可能会导致严重的伤害甚至死亡。插入后和使用前，需要确认胃管放置在胃中。传统上，确认试管正确放置的第一线方法是获取少量胃内容物并测试样品的酸度水平。胃内容物酸性很强，所以酸含量高的样本应该能证明管子是否正确放置。由于使用的试管直径较小，而且儿童胃内容物的量较少，因此难以获得此类样本，这可能导致酸测试不确定。如果发生这种情况，孩子将需要一个X光检查正确的位置。这种方法提供了管放置的准确确认，但涉及延迟和暴露于辐射的儿童。 监测呼出气中的二氧化碳（carbon dioxide，CO₂）是一种既定的工具，用于患者需要帮助更好地呼吸时的医学实践。有人建议，这种监测装置可以用于通过检测CO...

血管成形术或血管內支架置入对深部静脉栓塞患者的效用如何？ 关键信息 ⦁ 目前血管成形术或血管內支架置入对深部静脉栓塞(Deep vein thrombosis, DVT)患者的效用仍不清楚。 ⦁ 需要进一步的大型研究來确定，血管成形术或血管內支架置入对DVT患者是否是安全且有效的治疗。 什么是深部静脉栓塞(DVT)？ DVT是指血栓形成于深部静脉，通常位于腿部。它可能会导致患腿的疼痛、肿胀及发紅。DVT 也可能导致严重的并发症，例如血栓后症候群 (PTS)（DVT 后出现的慢性疾病）和肺栓塞 (PE)（当部分 DVT 血块脱落并进入肺部）。 DVT如何治疗呢？ DVT通常以血液稀释剂治疗，以防止血栓变大并阻止其脱落并进入肺部。DVT的其他治疗方法包括穿压力袜和手术（包含血管成形术和血管內支架植入）。血管成形术和血管內支架植入用于打通阻塞的血管并保持其畅通，这有助于改善血流并减轻症狀。 我们想要了解什么？ 我们想确定血管成形术或血管內支架植入对于DVT患者是否是一种安全且有效的治疗方法。 我们做了什么？ 我们评价了研究证据，探索血管成形术和血管內支架置入对DVT患者是否为安全且有效的治疗方法。我们比较和总结这些研究结果，并根据研究方法与规模评估证据的可信度。 我们发现了什么？ 我们找到两项研究共納入134名DVT患者。两项研究均在中国进行，持续了12至36个月。血管成形术或血管內支...

针对抑郁症的母乳喂养支持干预措施能否预防产后抑郁症的发展？ 关键信息 - 心理社会母乳喂养支持干预措施可能在获得支持后1至3个月内预防一些母亲产后抑郁症，并在获得支持后7至12个月内延长母乳喂养的持续时间。关于对其他心理健康和母乳喂养结局的影响的证据质量极低。 - 关于替代性母乳喂养干预措施（特别是正念）对产后抑郁症和其他心理健康及母乳喂养结局的影响的证据质量极低。 - 研究没有指出任何与干预直接相关的不良事件，但在大多数研究中，我们不知道是否已经测量过这个结局。 - 未来的母乳喂养干预研究应非常谨慎地进行，以降低偏倚风险，并且研究规模应足够大，以检测出母亲之间心理健康方面的差异。 什么是产后抑郁症？ 产后抑郁症是分娩后出现的一种心理健康状况，其特征是情绪低落或长时间对活动失去乐趣或兴趣。这种情况会对母亲、婴儿和整个家庭产生严重影响。 我们想知道什么？ 我们想了解针对抑郁症的母乳喂养支持干预是否比标准的产后护理更能预防产后抑郁症并减轻产后抑郁症的症状。我们还想了解母乳喂养支持干预是否有任何有害的副作用。 我们做了什么？ 2024 年 6 月，我们对随机对照临床试验（受试者被随机分配到干预组或对照组的研究）进行了文献综述，以了解母乳喂养支持干预是否可以预防产后抑郁症。我们的综述纳入10项研究，其中 9 项评估了接受心理社会支持（教育、心理帮助和社会支持的结合）的母亲，1 项评估了减...

We are pleased to announce that earlier this week, Cochrane’s status as a non-State actor (NSA) in official relations with the World Health Organization (WHO) was renewed at the 156th session of the WHO Executive Board meeting in Geneva.

The Executive Board is composed of 34 technically qualified representatives from different Member States, elected for three-year terms. Every year, the Executive Board meets at WHO headquarters to discuss global health priorities for the year ahead and sets the agenda for the World Health Assembly.

The renewal of our official relations status is underpinned by a new joint plan of work for the next three years, which focuses on providing WHO with evidence syntheses that will help inform guidelines, the essential medicines list, methodological assistance and training, supporting activities that facilitate the use of evidence in policymaking at country, regional and global levels, alongside other technical assistance.

This official relation status also enables us to join and make statements at key WHO meetings as a non-voting participant. This includes the World Health Assembly (WHA), WHO’s decision-making body, which is attended by representatives of all Member States, and is a key forum to advocate for evidence-informed health policies and resolutions.

Cochrane was represented at this year’s Executive Board meeting by Governing Board member, Emma Persad; CEO, Catherine Spencer; and Advocacy and Partnerships Officer, Mariam Salman.

The session began with an opening statement by Dr Tedros Adhanom Ghebreyesus, WHO Director-General. He highlighted the key achievements of the past 12 months and welcomed the adoption of the Fourteenth General Programme Of Work (GPW14), which Cochrane were invited to consult on through our NSA in official relations status.

He mentioned that maternal health is the theme for World Health Day this year and that although we have made progress on maternal and child mortality, we still have a long way to go to reach the Sustainable Development Goals (SDGs).

The Director-General also applauded Science Division, stating that its normative and standard-setting function is helping ensure that Member States are given the highest quality, evidence-based advice as fast as possible.

As part of the discussions, Cochrane submitted a statement to the Executive Board for consideration. Our statement supported the adoption of a draft resolution on strengthening national capacities in evidence-based decision making, as well as advocating for the production of high-quality evidence.  The full statement can be read below:

“Honorable Chair, Esteemed Delegates,

For over 30 years, the Cochrane Collaboration has been at the forefront of improving global health and life expectancy. We produce high-quality and trusted synthesized evidence to inform health decision making.

In a dramatically changing world with overlapping global health challenges, this is more vital now than ever.

We therefore urge Member States to adopt the Resolution titled “Strengthening national capacities in evidence-based decision making for the uptake and impact of norms and standards”

We also acknowledge that in order to ensure the production of high-quality evidence, the relevant WHO departments need core, recurrent funding for this essential function to continue its impact on a country-level.

We are pleased to see the alignment between WHO’s priorities and the Cochrane Collaboration’s Scientific Strategy, and express our sincerest gratitude and support in our ongoing engagement.”

• For more information on the work that Cochrane does with WHO and this year’s Executive Board meeting, please email msalman@cochrane.org.
• Find out more about the 156th session of the Executive Board.

Thursday, February 13, 2025

减缓儿童近视进展的干预措施 关键信息 药物治疗，例如阿托平 (Atropine) 眼药水的使用，可以减缓儿童近视度数的加深，还可以减少近视引起的眼球拉长。高剂量的阿托品最有效。我们不确定低剂量阿托品的效果。 一些治疗方法，包括特殊类型的眼镜镜片、隐形眼镜和使用低强度红光的新疗法，可能会减缓近视的发展，但它们的效果仍然不确定。关于控制近视的干预相关的不良副作用没有足够的信息。 报告的减缓近视进展的治疗不确定是否可以持续多年。 什么是近视？ 近视（或短视）是指人们难以看清远处的物体，而近处的物体仍保持清晰。它在世界范围内非常普遍，影响了中国和东南亚一半以上的儿童。近视可能会损害生活的许多方面，包括上学和职业活动。而且，近视的人眼球更长，这意味着视网膜被拉长了。这让眼睛在以后的生活种出现眼疾病的风险更高，例如青光眼、黄斑部病变以及视网膜剥离。 如何治疗近视？ 尽管传统的眼镜或隐形眼镜能够矫正近视，但它们并不能减缓近视的发展。目前有一些光学疗法（如眼镜与隐形眼镜）与药物旨在减缓近视的进展。近视治疗需要在儿童时期进行，因为此时近视发展最快。阿托品滴眼液等药物可能有效，但会导致对眩光的敏感性增加，并导致阅读时出现问题，尤其是在高剂量时。也可以使用在镜片内包含多个聚焦点的特殊眼镜（多焦点或周边离焦镜片）。这些也可以作为软性隐形眼镜提供。另一种隐形眼镜，叫做角膜塑形镜，旨在暂时改变眼球表面的形狀...

Honouring Cochrane's Volunteer Translators: Bridging Language Gaps in 2024

Cochrane proudly celebrates the incredible efforts of our volunteer translators in 2024. Their dedication has been instrumental in breaking language barriers and making high-quality health information accessible to communities worldwide.

This year, more than 730 volunteers actively contributed to our translation programme, with 48.6% coming from lower- or middle-income countries. Some language teams work with a larger number of volunteers than others, showcasing the diverse nature of our global multi-language programme.

In 2024 alone, our translation teams have published over 6,056 new or updated plain language summaries—and, for some languages, abstracts as well—bringing the total number of review summary translations to an impressive 54,272. This extraordinary collective effort ensures that Cochrane's trusted, evidence-based health information reaches those who need it most, regardless of the language they speak.

Beyond the numbers, the dedication of our volunteers is truly inspiring. Many of them balance their translation work with professional and personal commitments, yet they remain steadfast in their mission to improve global health literacy. 

Inès Belalem, volunteer in the French translation team, shared:

Pagakrong Lumbiganon from the Thai translation team reflected:

We extend our deepest gratitude to everyone involved in Cochrane’s translation projects for their unwavering commitment. Your contributions are invaluable, and together, we are making a meaningful impact on global health.

Thank you for being an essential part of Cochrane’s mission to provide accessible, high-quality health information to all.

About Cochrane's Multi-Language Programme

Cochrane translates evidence-based health information into multiple languages to improve accessibility and reduce linguistic barriers to global evidence-informed health decisions. We regularly translate content into languages including Croatian, Dutch, French, German, Hindi, Hungarian, Indonesian, Japanese, Korean, Malay, Persian, Polish, Portuguese, Romanian, Russian, Spanish, Simplified Chinese, Thai, and Traditional Chinese.

Only around 6% of the world’s population are native English speakers, and 75% of people do not speak English at all. Many individuals lack access to high-quality health information simply because it is not available in a language they understand. By translating Cochrane evidence, we aim to bridge this gap and ensure that everyone, regardless of language, can make informed health decisions.

•  If you are interested in joining our community of volunteer translators and contributing to this vital work, please click here for more information on how to get involved.

 

Monday, February 3, 2025

Thursday, January 30, 2025